Saundra Pelletier, Evofem CEO
October 12, 2022 10:38 AM EDT
R&D

Evofem's ap­proved birth con­trol gel flops PhI­II for STI pre­ven­tion, ear­ly 2023 fil­ing plans ditched

Kyle LaHucik

Senior Reporter

A biotech with an ap­proved non-hor­mon­al birth con­trol gel had hoped it would be at the FDA’s doorsteps in ear­ly 2023 to re­quest a la­bel …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times